Cargando…
In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study
Iclaprim is a bacterial dihydrofolate reductase inhibitor in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections and hospital-acquired bacterial pneumonia caused by Gram-positive bacteria. Daptomycin, linezolid, and vancomycin are commonly used antibi...
Autores principales: | Huang, David B., Hawser, Stephen, Gemmell, Curtis G., Sahm, Daniel F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748095/ https://www.ncbi.nlm.nih.gov/pubmed/29527229 http://dx.doi.org/10.1155/2017/3948626 |
Ejemplares similares
-
1588. Delafloxacin Activity Against Staphylococcus aureus with Reduced Susceptibility or Resistance to Methicillin, Vancomycin, Daptomycin, or Linezolid
por: Saravolatz, Louis D, et al.
Publicado: (2019) -
Vancomycin, teicoplanin, daptomycin, and linezolid MIC creep in methicillin-resistant Staphylococcus aureus is associated with clonality
por: Hsieh, Yu-Chia, et al.
Publicado: (2016) -
Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid–Nonsusceptible Vancomycin-Resistant Enterococcus
por: Greene, Matthew H, et al.
Publicado: (2018) -
Evolution of Multi-Resistance to Vancomycin, Daptomycin, and Linezolid in Methicillin-Resistant Staphylococcus aureus Causing Persistent Bacteremia
por: Chen, Chih-Jung, et al.
Publicado: (2020) -
711. Molecular Epidemiology of Daptomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia
por: Sundaram, Ayesha, et al.
Publicado: (2018)